Pharmacokinetics of amikacin in the horse following intravenous and intramuscular administration.

This research article focuses on the study of how amikacin sulfate, an antibiotic, behaves in the body of a horse when given by intravenous and intramuscular injections. The investigation is carried out across different injection doses and frequencies, and the drug’s concentrations in several bodily fluids are measured. The results indicate the most effective dose and frequency for therapeutic use.

Method of Research

• The research team conducted a study on the pharmacokinetics of amikacin sulfate (often used as an antibiotic) in horses. Pharmacokinetics studies how a drug is absorbed, distributed, metabolized, and excreted in the body.
• The drug was administered in two ways: intravenous (i.v.) and intramuscular (i.m.) injections.
• Different doses were given including 4.4, 6.6, and 11.0 mg/kg to understand the dose-dependent behavior of the drug.
• The drug’s concentrations in different biological fluids namely serum (Cs), synovial fluid (Csf), and peritoneal fluid (Cpf) were measured.

Key Findings

• The concentration of the drug at 15 mins following the i.v. injection was directly proportional to the dose. The higher the dose, the greater the concentration.
• The peak concentration values in the serum post intramuscular injections were observed at about 1 hour after the injection. The concentration value was again directly proportional to the injected dose.
• The half-life (t 1/2) of amikacin varied slightly across different doses with recorded times at 1.44, 1.57, and 1.14 hours for 4.4, 6.6, and 11.0 mg/kg doses respectively.
• The study also determined the minimum inhibitory concentrations (MIC) of amikacin sulfate for six different pathogens. The MIC is the lowest concentration of a drug that prevents the visible growth of a bacterium.

Theoretical Implications

• Beyond understanding the behavior of amikacin sulfate in horses’ bodies, this study helped determine optimal dosing schedules to maximize therapeutic effects.
• By measuring the MIC and studying the pharmacokinetic parameters, the researchers were able to provide a suggested therapeutic dose. The regular treatment of amikacin should fall between 4.4 and 6.6 mg/kg given twice daily.
• In case of serious, life-threatening infections, the dose could be increased and administered three times a day to combat the severity of the infection effectively.